Opioid, alcohol, and cannabis misuse among patients with hidradenitis suppurativa: A population-based analysis in the United States - 16/08/18
, Vassiliki Papagermanos, BA a, Margaretta Midura, BA a, Andrew Strunk, MA a, Jonathan Merson, MD bAbstract |
Background |
Patients with hidradenitis suppurativa (HS) experience chronic pain and have significant physical, emotional, and psychological disease impact. These patients may be at risk for substance abuse.
Objective |
To evaluate substance use disorder (SUD) among patients with HS in the United States.
Methods |
This cross-sectional analysis of adult HS patients (n = 32,625) identified using electronic health records data was pulled from a population-based sample of >50 million patients.
Results |
The prevalence of SUD among patients with HS was 4.0% (1315/32,625) compared to 2.0% (195,260/9,581,640) for patients without HS (P < .001). The most common forms of substance misuse among HS patients were alcohol (630/1315, 47.9% of SUD cases), followed by opioids (430/1315, 32.7% of SUD cases) and cannabis (430/1315, 29.7% of SUD cases). Patients with HS had 1.50 (95% confidence interval 1.42-1.59) times the adjusted odds of SUD compared to patients without HS. Patients with HS had significantly greater odds of SUD across demographic subgroups. The association between HS and SUD was generally stronger for patients 45 to 64 years of age, nonwhites, privately insured, and those without depressive or anxiety disorder.
Limitations |
SUD may not be accurately diagnosed.
Conclusion |
Patients with HS have higher odds of SUD and may benefit from periodic screening for substance abuse.
Le texte complet de cet article est disponible en PDF.Key words : alcohol, cannabis, Explorys, opioid, hidradenitis suppurativa, misuse, substance use
Abbreviations used : HS, ICD-9, LOINC, QOL, SNOMED-CT, SUD
Plan
| Ms Midura and Mr Papagermanos contributed equally to this article. |
|
| Supported in part by an education grant from AbbVie. The sponsor has had no role in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; decision to submit the manuscript for publication. |
|
| Dr Garg has served as an advisor for AbbVie, Pfizer, Janssen, and Asana Biosciences, and has received honoraria. |
|
| Reprints not available from the authors. |
Vol 79 - N° 3
P. 495 - septembre 2018 Retour au numéro
Article précédent
- CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris
- Brittany G. Craiglow, Lynn M. Boyden, Ronghua Hu, Marie Virtanen, John Su, Gabriela Rodriguez, Catherine McCarthy, Paula Luna, Margarita Larralde, Stephen Humphrey, Kristen E. Holland, Marcia Hogeling, Benjamin Hidalgo-Matlock, Bruno Ferrari, Esteban Fernandez-Faith, Beth Drolet, Kelly M. Cordoro, Anne M. Bowcock, Richard J. Antaya, Kurt Ashack, Richard J. Ashack, Richard P. Lifton, Leonard M. Milstone, Amy S. Paller, Keith A. Choate
- Impact of topical fluorouracil cream on costs of treating keratinocyte carcinoma (nonmelanoma skin cancer) and actinic keratosis
- Jean Yoon, Ciaran S. Phibbs, Adam Chow, Martin A. Weinstock, Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?